Compare DexCom, Inc. (DXCM) vs Freeport-McMoRan Inc (FCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Freeport-McMoRan Inc — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Freeport-McMoRan Inc trades at $73.69 (market cap $102.16B). The key difference: Freeport-McMoRan Inc is far larger — about 3.2× DexCom, Inc.'s market cap, and Freeport-McMoRan Inc pays a 0.84% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Freeport-McMoRan Inc for 69 Days on average.
| DXCM | FCX | |
|---|---|---|
Market Cap | $31.86B | $102.16B |
Volume | 3,607,070 | 9,047,971 |
Sector | Health | Basic Materials |
52-Week High | $92.34 | $79.91 |
52-Week Low | $54.84 | $38.65 |
Typical Hold Time | 62 Days | 69 Days |
Enterprise Value | $31.32B | $108.44B |
Dividend Yield | — | 0.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
FCX trades at $71.13, down 1.02% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.68 exceeding the $0.60 estimate. Revenue for 2025 was $25.92B, with net income of $2.20B and an 11.38% net margin. Analyst consensus is a Buy with a $73.27 price target, and recent news highlights copper demand growth driven by AI and data centers.
FCX presents a positive outlook supported by robust copper demand trends and expansion projects, though rising production costs and a bearish technical picture pose near-term risks. The stock offers potential upside to the consensus target, but investors should monitor cost pressures and quarterly execution against expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →
